HomeELVN • NASDAQ
add
Enliven Therapeutics Inc
Previous close
$29.73
Day range
$29.66 - $30.78
Year range
$13.30 - $30.78
Market cap
1.81B USD
Avg Volume
757.25K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 34.28M | 27.47% |
Net income | -29.67M | -27.99% |
Net profit margin | — | — |
Earnings per share | -0.48 | — |
EBITDA | -34.24M | -27.68% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 462.62M | 47.59% |
Total assets | 476.17M | 46.17% |
Total liabilities | 16.57M | 4.10% |
Total equity | 459.60M | — |
Shares outstanding | 59.80M | — |
Price to book | 3.85 | — |
Return on assets | -17.73% | — |
Return on capital | -18.30% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -29.67M | -27.99% |
Cash from operations | -15.84M | 7.93% |
Cash from investing | 12.38M | 1,602.75% |
Cash from financing | 623.00K | -98.44% |
Net change in cash | -2.84M | -112.07% |
Free cash flow | -14.30M | -19.78% |
About
Founded
2016
Headquarters
Website
Employees
60
